Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Veliparib (ABT-888) in Combination With Cisplatin Plus Gemcitabine in Advanced Biliary, Pancreatic, Urothelial, and Non-small Cell Lung Cancer

NCT01282333 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01282333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01282333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Veliparib (ABT-888) in Combination With Cisplatin Plus Gemcitabine in Advanced Biliary, Pancreatic, Urothelial, and Non-small Cell Lung Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2011
Completion date
Not reported
Enrollment
44 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced adult primary liver cancer, localized unresectable adult primary liver cancer, metastatic transitional cell cancer of the renal pelvis and ureter, regional transitional cell cancer of the renal pelvis and ureter, stage iii bladder cancer, stage iii pancreatic cancer, stage iiia non-small cell lung cancer, stage iiib non-small cell lung cancer, stage iv bladder cancer, stage iv non-small cell lung cancer, stage iv pancreatic cancer, transitional cell carcinoma of the bladder, unresectable extrahepatic bile duct cancer, unresectable gallbladder cancer